The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.
 
Keitaro Shimozaki
No Relationships to Disclose
 
Koshiro Fukuda
No Relationships to Disclose
 
Akira Ooki
Honoraria - Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo; Ono Pharmaceutical
 
Izuma Nakayama
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Koichiro Yoshino
No Relationships to Disclose
 
Shohei Udagawa
No Relationships to Disclose
 
Shota Fukuoka
No Relationships to Disclose
 
Hiroki Osumi
No Relationships to Disclose
 
Mariko Ogura
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Daisuke Takahari
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Keisho Chin
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)